About Alizé Pharma
Alizé Pharma is a Healthcare company based in Ecully (France) founded in 2007, and was acquired by Millendo Therapeutics in December 2017. Develop drugs, proteins and peptides for the treatment of metabolic and rare diseases. Alizé Pharma has raised $94.35 million across 7 funding rounds from investors including Crédit Agricole, Orbimed and Bpifrance. Alizé Pharma offers products and services including Enhertu and AstraZeneca Vaccines. Its focus areas include Diversified Pharmaceuticals.
Company details
Alizé Pharma was established in 2007 in Ecully, France, within the biotechnology sector. Emphasis is placed on the development of drugs, proteins, and peptides targeted at metabolic and rare diseases. Research and development operations are conducted to create therapeutic solutions for these conditions, with activities focused on addressing specific unmet needs in patient care across Europe.
- Headquarters Ecully, France
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website alz-pharma.com
- Social LinkedIn
- Acquired by Millendo Therapeutics (Dec 2017)
- Total Equity Funding$94.35M (USD)
in 7 rounds
- Latest Funding Round$75M (USD), Series A
Jul 2019
- InvestorsCrédit Agricole
& 14 more
- Acquired byMillendo Therapeutics
(Dec 2017)
Products & Services of Alizé Pharma
Alizé Pharma offers a comprehensive portfolio of products and services, including Enhertu and AstraZeneca Vaccines.
Targets HER2-positive metastatic breast cancer for improved progression-free survival
Develops vaccines and therapies for infectious diseases and immune protection
Funding Insights of Alizé Pharma
Alizé Pharma has successfully raised a total of $94.35M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $75 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $94.35M
- Total Rounds 7
- Last Round Series A — $75M
- First Round $970,851
(Sep 2007)
- Investors Count 14
All 7 funding rounds of Alizé Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $75M | Series A | – | Life Sciences Partners | |
| Mar 2015 | $1.94M | Series A | – | – | |
| Sep 2014 | $6.44M | Series A | – | – | |
| Jun 2012 | $4.1M | Series A | – | – | |
| Sep 2009 | $4.2M | Series A | – | – | |
| May 2008 | $1.7M | Seed | – | – | |
| Sep 2007 | $970,851 | Seed | – | – |
15 investors in total: 15 institutional.
Investors in Alizé Pharma
Alizé Pharma has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Crédit Agricole, Orbimed and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity investments are made in companies across diverse sectors. | turennecapital.com | Paris, France | ||
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Octalfa is engaged in creating and supporting innovative companies. | 2007 | initiative-octalfa.eu | Lyon, France | |
Kreaxi is engaged in equity financing for innovative startups. | kreaxi.com | Limonest, France | ||
| sofimac-im.com | ||||
| partnersinnovationfund.com |
Investor details for Alizé Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Alizé Pharma
4 dated milestones of Alizé Pharma across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Alizé Pharma is founded.
- Funding First funding round of $971K.
- Exit Acquired by Millendo Therapeutics.
- Funding Latest funding round, Series A, of $75.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alizé Pharma
Complete news archive for Alizé Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alizé Pharma
Alizé Pharma was founded in 2007.
Alizé Pharma is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.
Alizé Pharma is a funded company, having raised a total of $94.35M across 7 funding rounds to date. The company's 1st funding round was a Seed of $970.85K, raised on Sep 2007.
Alizé Pharma was established in 2007 in Ecully, France, within the biotechnology sector. Emphasis is placed on the development of drugs, proteins, and peptides targeted at metabolic and rare diseases. Research and development operations are conducted to create therapeutic solutions for these conditions, with activities focused on addressing specific unmet needs in patient care across Europe.
Alizé Pharma offers Enhertu and AstraZeneca Vaccines.
Alizé Pharma has 15 investors. Key investors include Crédit Agricole, Orbimed, Bpifrance, Kurma Partners, and Life Sciences Partners.
Yes. Alizé Pharma was acquired by Millendo Therapeutics in December 2017.